On September 29, 2025, Dogwood Therapeutics, Inc. entered into a licensing agreement with Serpin Pharma, acquiring rights to develop an intravenous formulation (SP16) for treating chemotherapy-induced peripheral neuropathy; in return, Dogwood will issue 382,034 shares of common and preferred stock.